RSV vaccine update and Shingrix vaccine roll-out
On-demand recorded 14 Nov 2023
Latest information on future RSV vaccine and roll-out of Shingrix vaccine under the National Immunisation Program to support practitioners to offer vaccines strategically and opportunistically to their patients.
In this webinar, participants will receive an update on the current state of the RSV vaccine development and roll-out of Shingrix vaccine to help ensure they are well positioned to support their patients.
Learning outcomes
- Outline prevention strategies and the global burden of RSV disease in NSW and Australia
- Summarise the RSV vaccine and monoclonal antibody technology landscape and the various clinical trials
- Outline efficacy and safety of the RSV vaccines in different cohorts
- Outline disease pattern for herpes zoster (shingles) and vaccine coverage in elderly individuals
- Outline eligibility for free Shingrix vaccine under the National Immunisation Program
- Outline clinical recommendations on the Shingrix vaccine schedule and administration for immunisation providers
Facilitator
Dr Linda Mann
MBBS, FRACGP, DipRANZCOG, BScMED
Dr Mann is a Fellow of the RACGP and member of the RACGP Antenatal and Postnatal Care Network. Linda has both local and international medical experience, especially in genetics and woman’s health. Linda is a GP representative on various national and local government committees and is an experienced medical educator.
Speakers
Professor Nicholas Wood
MBBS, MPH, FRACP, PhD, Associate Director, Clinical Research and Services, Senior Staff Specialist, NCIRS
Nick Wood is a senior staff specialist general paediatrician and Professor in Clinical Vaccinology at the University of Sydney. Nick leads the NSW Immunisation Specialist Service and coordinates the Immunisation Adverse Events Clinic at The Children’s Hospital at Westmead. He is a senior investigator on the Primary Health Network immunisation Support program. Nick is interested in maternal and neonatal immunisation, as well as research into vaccine safety, including genetics and long-term outcomes of adverse events following immunisation.
Dr Jean Li-Kim-Moy
Staff Specialist-Immunisation and General Pediatrician, NCIRS
Dr Li-Kim-Moy is a staff specialist in Immunisation at the National Centre for Immunisation Research and Surveillance. He is involved in the Research to Inform Policy team which provides support to the Australian Technical Advisory Group on Immunisation (ATAGI). He has assisted ATAGI in its evaluation of numerous vaccines including influenza, meningococcal, COVID-19, RSV and herpes zoster vaccines. He is also a general paediatrician working in community paediatrics and neonatal care.